Avadel Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2001
Cash & Equivalents	31.17	73.98	50.71	71.72	9.77	9.33	16.56	39.22	65.06	39.76	Upgrade
Short-Term Investments	73.94	22.52	106.51	149.68	54.38	90.59	77.51	114.98	79.74	53.07	Upgrade
Cash & Cash Equivalents	105.11	96.5	157.22	221.4	64.16	99.92	94.08	154.2	144.8	92.83	Upgrade
Cash Growth	8.92%	-38.62%	-28.99%	245.09%	-35.79%	6.21%	-38.99%	6.49%	55.98%	1219.23%	Upgrade
Receivables	12.1	0	0	0	8.28	11.33	14.79	17.84	7.49	1.68	Upgrade
Inventory	10.38	0	0	0	3.57	4.77	6.16	3.26	3.67	6.73	Upgrade
Other Current Assets	6.61	4.34	35.27	42.05	6.37	8.84	8.96	5.89	10.45	11.08	Upgrade
Total Current Assets	134.2	100.84	192.49	263.45	82.38	124.85	123.98	181.19	166.4	112.32	Upgrade
Property, Plant & Equipment	3.18	2.55	2.94	2.96	4.16	1.91	3	3.32	2.62	1.78	Upgrade
Goodwill and Intangibles	16.84	16.84	16.84	16.84	19.3	20.12	110.78	41.33	34.32	46.88	Upgrade
Other Long-Term Assets	10.48	12.55	35	28.38	45.6	43.42	15.52	19.65	11.75	13.23	Upgrade
Total Long-Term Assets	30.5	31.94	54.78	48.18	69.06	65.45	129.3	64.3	48.68	61.88	Upgrade
Total Assets	164.7	132.79	247.27	311.64	151.44	190.3	253.28	245.48	215.08	174.21	Upgrade
Accounts Payable	11.43	7.89	7.68	2.93	6.1	12.94	32.48	41.28	127.74	8.02	Upgrade
Deferred Revenue	0	0	0	0	0	0	2.01	2.22	5.12	1.34	Upgrade
Current Debt	0.93	38.63	0.9	0.47	0.65	0.11	0.11	0.27	0.43	2.44	Upgrade
Other Current Liabilities	24.49	9.28	12.42	11.7	29.24	25.34	51.94	18.65	-88.05	59.04	Upgrade
Total Current Liabilities	36.86	55.79	21	15.11	35.98	38.38	86.54	62.42	45.25	70.84	Upgrade
Long-Term Debt	34.45	92.39	144.1	130.05	124.01	135.14	74.07	135.72	0.68	1.28	Upgrade
Other Long-Term Liabilities	5.65	5.74	3.92	4.21	20.65	14	7.08	5.28	100.02	77.19	Upgrade
Total Long-Term Liabilities	40.1	98.14	148.02	134.26	144.65	149.14	81.16	140.99	100.7	78.47	Upgrade
Total Liabilities	76.96	153.93	169.02	149.37	180.64	187.52	167.7	203.41	145.95	149.31	Upgrade
Total Debt	35.38	131.02	145	130.52	124.65	135.24	74.19	135.99	1.12	3.72	Upgrade
Debt Growth	-72.99%	-9.64%	11.09%	4.71%	-7.83%	82.30%	-45.45%	12063.24%	-69.92%	-95.65%	Upgrade
Retained Earnings	-745.5	-585.22	-447.76	-384.19	-391.22	-357.99	-262.69	-319.8	-278.52	-320.45	Upgrade
Comprehensive Income	-23.17	-26.34	-23.94	-21.05	-22.81	-23.42	-23.27	-23.57	-22.66	-7.42	Upgrade
Shareholders' Equity	87.74	-21.15	78.24	162.27	-29.2	2.78	85.58	42.07	69.13	24.9	Upgrade
Net Cash / Debt	69.73	-34.52	12.22	90.88	-60.49	-35.33	19.89	18.21	143.68	89.12	Upgrade
Net Cash / Debt Growth	-	-	-86.56%	-	-	-	9.23%	-87.33%	61.23%	-	Upgrade
Net Cash Per Share	0.87	-0.57	0.21	1.65	-1.62	-0.95	0.48	0.44	3.29	2.46	Upgrade
Working Capital	97.35	45.05	171.49	248.35	46.4	86.47	37.44	118.77	121.15	41.48	Upgrade
Book Value Per Share	1.09	-0.35	1.34	3.06	-0.78	0.07	2.12	1.02	1.70	0.69	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).